• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

EPHA3可能是一种新型的预后生物标志物，且与膀胱癌中的免疫浸润相关。

EPHA3 Could Be a Novel Prognosis Biomarker and Correlates with Immune Infiltrates in Bladder Cancer.

作者信息

Liu Junpeng, Zhou Zewen, Jiang Yifan, Lin Yuzhao, Yang Yunzhi, Tian Chongjiang, Liu Jinwen, Lin Hao, Huang Bin

机构信息

Department of Urology, The Second Affiliated Hospital of Shantou University, Medical College, Shantou 515041, China.

Department of Urology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou 510700, China.

出版信息

Cancers (Basel). 2023 Jan 19;15(3):621. doi: 10.3390/cancers15030621.

DOI:10.3390/cancers15030621
PMID:36765579
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9913674/
Abstract

PURPOSE

To assess the mechanism of EPH receptor A3 (EPHA3) and its potential value for immunotherapy in BLCA.

MATERIALS AND METHODS

The Cancer Genome Atlas (TCGA) bladder cancer (BLCA) database and the Gene Expression Omnibus (GEO) database were used for assessing whether EHPA3 could be used to predict BLCA prognosis. This work carried out in vitro and in vivo assays for exploring how EPHA3 affected the biological behaviors. The downstream pathway was explored using a Western blotting technique. The CIBERSORT, ESTIMATE, TIMER, and TIDE tools were used to predict the immunotherapy value of EPHA3 in BLCA.

RESULTS

EPHA3 was poorly expressed in BLCA ( < 0.05), its high expression is related to a good survival prognosis ( = 0.027 and = 0.0275), and it has a good predictive ability for the histologic grade and status of BLCA (area under curve = 0.787 and 0.904). Overexpressed EPHA3 could inhibit BLCA cell biological behaviors, and it be associated with the downregulation of the Ras/ERK1/2 pathway. EPHA3 was correlated with several immune-infiltrating cells and the corresponding marker genes.

CONCLUSIONS

EPHA3 could be regarded as an acceptable anti-cancer biomarker in BLCA. EPHA3 plays an inhibiting role in BLCA, and it could be the candidate immunotherapeutic target for BLCA.

摘要

目的

评估EPH受体A3（EPHA3）在膀胱癌（BLCA）中的作用机制及其免疫治疗的潜在价值。

材料与方法

利用癌症基因组图谱（TCGA）膀胱癌（BLCA）数据库和基因表达综合数据库（GEO）评估EHPA3是否可用于预测BLCA预后。开展体内外实验以探究EPHA3如何影响生物学行为。采用蛋白质印迹技术探索下游通路。使用CIBERSORT、ESTIMATE、TIMER和TIDE工具预测EPHA3在BLCA中的免疫治疗价值。

结果

EPHA3在BLCA中低表达（<0.05），其高表达与良好的生存预后相关（=0.027和=0.0275），并且对BLCA的组织学分级和状态具有良好的预测能力（曲线下面积=0.787和0.904）。过表达的EPHA3可抑制BLCA细胞的生物学行为，并且与Ras/ERK1/2通路的下调有关。EPHA3与多种免疫浸润细胞及相应的标记基因相关。

结论

EPHA3可被视为BLCA中一种可接受的抗癌生物标志物。EPHA3在BLCA中发挥抑制作用，并且可能是BLCA的候选免疫治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c85/9913674/e96199e81a9c/cancers-15-00621-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c85/9913674/e770b05d4759/cancers-15-00621-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c85/9913674/1397886cdfeb/cancers-15-00621-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c85/9913674/fead80521cc0/cancers-15-00621-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c85/9913674/c00f305bd346/cancers-15-00621-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c85/9913674/f64bc44f8453/cancers-15-00621-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c85/9913674/a5def0488f72/cancers-15-00621-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c85/9913674/573668dc89bd/cancers-15-00621-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c85/9913674/1f79b10a0aa5/cancers-15-00621-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c85/9913674/1b640d287d89/cancers-15-00621-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c85/9913674/176304cb0fb1/cancers-15-00621-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c85/9913674/33877bb9a5e2/cancers-15-00621-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c85/9913674/591dd78152a3/cancers-15-00621-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c85/9913674/90ec2667be2e/cancers-15-00621-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c85/9913674/e96199e81a9c/cancers-15-00621-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c85/9913674/e770b05d4759/cancers-15-00621-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c85/9913674/1397886cdfeb/cancers-15-00621-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c85/9913674/fead80521cc0/cancers-15-00621-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c85/9913674/c00f305bd346/cancers-15-00621-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c85/9913674/f64bc44f8453/cancers-15-00621-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c85/9913674/a5def0488f72/cancers-15-00621-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c85/9913674/573668dc89bd/cancers-15-00621-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c85/9913674/1f79b10a0aa5/cancers-15-00621-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c85/9913674/1b640d287d89/cancers-15-00621-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c85/9913674/176304cb0fb1/cancers-15-00621-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c85/9913674/33877bb9a5e2/cancers-15-00621-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c85/9913674/591dd78152a3/cancers-15-00621-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c85/9913674/90ec2667be2e/cancers-15-00621-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c85/9913674/e96199e81a9c/cancers-15-00621-g014.jpg

相似文献

1
EPHA3 Could Be a Novel Prognosis Biomarker and Correlates with Immune Infiltrates in Bladder Cancer.EPHA3可能是一种新型的预后生物标志物，且与膀胱癌中的免疫浸润相关。
Cancers (Basel). 2023 Jan 19;15(3):621. doi: 10.3390/cancers15030621.
2
Prognostic value of COL10A1 and its correlation with tumor-infiltrating immune cells in urothelial bladder cancer: A comprehensive study based on bioinformatics and clinical analysis validation.COL10A1 在尿路上皮膀胱癌中的预后价值及其与肿瘤浸润免疫细胞的相关性：基于生物信息学和临床分析验证的综合研究。
Front Immunol. 2023 Mar 17;14:955949. doi: 10.3389/fimmu.2023.955949. eCollection 2023.
3
HYAL3 as a potential novel marker of BLCA patient prognosis.HYAL3 作为膀胱癌患者预后的一个潜在新型标志物。
BMC Genom Data. 2022 Aug 9;23(1):63. doi: 10.1186/s12863-022-01070-w.
4
Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.开发和验证一种新型的与脂质代谢相关的基因预后标志物，并为膀胱癌患者找到候选药物。
Lipids Health Dis. 2021 Oct 27;20(1):146. doi: 10.1186/s12944-021-01554-1.
5
Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.鉴定一个与肿瘤微环境相关的七基因标志物，用于预测膀胱癌的预后。
BMC Cancer. 2021 Jun 10;21(1):692. doi: 10.1186/s12885-021-08447-7.
6
Tumor Expression Profile Analysis Developed and Validated a Prognostic Model Based on Immune-Related Genes in Bladder Cancer.肿瘤表达谱分析建立并验证了一种基于膀胱癌免疫相关基因的预后模型。
Front Genet. 2021 Aug 27;12:696912. doi: 10.3389/fgene.2021.696912. eCollection 2021.
7
PRR11 is a prognostic biomarker and correlates with immune infiltrates in bladder urothelial carcinoma.PRR11 是一种预后生物标志物，与膀胱尿路上皮癌的免疫浸润相关。
Sci Rep. 2023 Feb 4;13(1):2051. doi: 10.1038/s41598-023-29316-2.
8
High expression of predicts a poor prognosis and correlates with immune infiltrates in bladder urothelial carcinoma.[具体物质]的高表达预示着膀胱癌患者预后不良，并与免疫浸润相关。 （注：原文中“High expression of ”后缺少具体物质，这里用“[具体物质]”表示原文缺失部分）
Oncol Lett. 2020 Sep;20(3):2840-2854. doi: 10.3892/ol.2020.11841. Epub 2020 Jul 9.
9
A novel focal adhesion-related risk model predicts prognosis of bladder cancer -- a bioinformatic study based on TCGA and GEO database.一种新的与焦点黏附相关的风险模型预测膀胱癌的预后——基于 TCGA 和 GEO 数据库的生物信息学研究。
BMC Cancer. 2022 Nov 10;22(1):1158. doi: 10.1186/s12885-022-10264-5.
10
Tumor Microenvironment Analysis Identified Subtypes Associated With the Prognosis and the Tumor Response to Immunotherapy in Bladder Cancer.肿瘤微环境分析确定了与膀胱癌预后及肿瘤免疫治疗反应相关的亚型。
Front Genet. 2021 Mar 1;12:551605. doi: 10.3389/fgene.2021.551605. eCollection 2021.

引用本文的文献

1
Clinicopathological characteristics and genetic features of young and senior Ewing sarcoma patients.青年和老年尤文肉瘤患者的临床病理特征和遗传特征。
Diagn Pathol. 2024 Sep 16;19(1):124. doi: 10.1186/s13000-024-01548-4.
2
Predictive and Prognostic Relevance of Tumor-Infiltrating Immune Cells: Tailoring Personalized Treatments against Different Cancer Types.肿瘤浸润免疫细胞的预测和预后相关性：针对不同癌症类型定制个性化治疗
Cancers (Basel). 2024 Apr 23;16(9):1626. doi: 10.3390/cancers16091626.
3
Expression pattern, tumor immune landscape, and prognostic value of N7‑methylguanosine regulators in bladder urothelial carcinoma.

本文引用的文献

1
TTYH3 Modulates Bladder Cancer Proliferation and Metastasis via FGFR1/H-Ras/A-Raf/MEK/ERK Pathway.TTYH3 通过 FGFR1/H-Ras/A-Raf/MEK/ERK 通路调节膀胱癌的增殖和转移。
Int J Mol Sci. 2022 Sep 10;23(18):10496. doi: 10.3390/ijms231810496.
2
CDC42 Regulates Cell Proliferation and Apoptosis in Bladder Cancer via the IQGAP3-Mediated Ras/ERK Pathway.CDC42 通过 IQGAP3 介导的 Ras/ERK 通路调控膀胱癌细胞增殖和凋亡。
Biochem Genet. 2022 Dec;60(6):2383-2398. doi: 10.1007/s10528-022-10223-6. Epub 2022 Apr 12.
3
Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective.
N7-甲基鸟苷调节剂在膀胱尿路上皮癌中的表达模式、肿瘤免疫景观及预后价值
Oncol Lett. 2023 Mar 10;25(4):169. doi: 10.3892/ol.2023.13755. eCollection 2023 Apr.
非肌肉浸润性膀胱癌的复发机制——临床视角。
Nat Rev Urol. 2022 May;19(5):280-294. doi: 10.1038/s41585-022-00578-1. Epub 2022 Mar 31.
4
[Transurethral resection of bladder tumors (TURBT)].经尿道膀胱肿瘤切除术（TURBT）
Urologe A. 2022 Jan;61(1):71-82. doi: 10.1007/s00120-021-01741-z. Epub 2022 Jan 4.
5
Cell-Extrinsic Differentiation Block Mediated by EphA3 in Pre-Leukaemic Thymus Contributes to Disease Progression.EphA3介导的白血病前期胸腺细胞外分化阻滞促进疾病进展。
Cancers (Basel). 2021 Jul 31;13(15):3858. doi: 10.3390/cancers13153858.
6
Combination Therapy With Immune Checkpoint Inhibitors in Urothelial Carcinoma: Current Data and Future Outlook.尿路上皮癌中免疫检查点抑制剂的联合治疗：当前数据与未来展望
Oncology (Williston Park). 2021 Jul 15;35(7):410-420. doi: 10.46883/ONC.2021.3507.0410.
7
Promoter hypomethylation as potential confounder of Ras gene overexpression and their clinical significance in subsets of urothelial carcinoma of bladder.启动子低甲基化可能是 Ras 基因过表达的混杂因素，及其在膀胱尿路上皮癌亚组中的临床意义。
Mol Biol Rep. 2021 Mar;48(3):2183-2199. doi: 10.1007/s11033-021-06227-x. Epub 2021 Feb 23.
8
Locoregional recurrence after cystectomy in muscle invasive bladder cancer: Implications for adjuvant radiotherapy.肌层浸润性膀胱癌膀胱切除术后局部区域复发：辅助放疗的意义。
Urol Oncol. 2021 Aug;39(8):496.e9-496.e15. doi: 10.1016/j.urolonc.2021.01.015. Epub 2021 Feb 9.
9
The Role of the Eph Receptor Family in Tumorigenesis.Eph受体家族在肿瘤发生中的作用。
Cancers (Basel). 2021 Jan 8;13(2):206. doi: 10.3390/cancers13020206.
10
Survival after radical cystectomy: Progressive versus De novo muscle invasive bladder cancer.根治性膀胱切除术的生存：进展性与新发性肌层浸润性膀胱癌。
Cancer Treat Res Commun. 2020;25:100264. doi: 10.1016/j.ctarc.2020.100264. Epub 2020 Dec 4.